

This document only includes an excerpt of the corresponding thesis or dissertation. To request a digital scan of the full text, please contact the Ruth Lilly Medical Library's Interlibrary Loan Department (rlmlill@iu.edu).


NEUROPEPTIDE TREATMENT IN EPILEPSY:
AN INTRANASAL APPROACH

Michael C. Veronesi


Submitted to the faculty of the University Graduate School
in partial fulfillment of the requirements
for the degree
Doctor of Philosophy
in the Department of Medical Neuroscience,
Indiana University

March 2008

Accepted by the Faculty of Indiana University, in partial fulfillment of the requirements for the degree of Doctor of Philosophy.




Michael Kubek, Ph.D.
(Chairperson)




Jay Simon, Ph.D.

Doctoral Committee




Vincent Gattone, Ph.D.

Date of
Oral Examination: 12/12/2007



Robert Worth M.D., Ph.D.



Asok Sen, Ph.D.

ABSTRACT

Michael C. Veronesi

NEUROPEPTIDE TREATMENT IN EPILEPSY: AN INTRANASAL APPROACH

A major barrier to entry of neuropeptides into the brain is low bioavailability and presence of the blood-brain barrier. Intranasal delivery of neuropeptides provides a potentially promising alternative to other routes of administration since a direct pathway exists between the olfactory neuroepithelium and the brain. We have determined the location of fluorescent molecules released from sustained-release biodegradable polylactide nanoparticles within the brain parenchyma following intranasal delivery and the time course for uptake during fluorescence microscopic visualization in several subregions. Fluorescence microscopy of dye-loaded and dye-attached NPs provided additional data on the uptake and transport of NPs in neuronal processes *in vitro*.

TRH is known to have anticonvulsant effects in several animal seizure models and is efficacious in treating patients with certain intractable epilepsies. The kindling paradigm, as a model of temporal lobe epilepsy, was used to show that intranasal administration of a TRH analog, 3-Methyl-Histidine TRH (3Me-H TRH) significantly inhibits seizure characteristics in fully kindled animals at 30 and 60 min prior to seizure induction. More importantly, polylactide nanoparticles containing TRH (TRH-NPs) applied during kindling acquisition modulates seizure duration, severity and number of stimulations to reach stage 5 and the fully kindled state.

Since Glutamate (Glu) toxicity has been implicated in neurodegenerative (epilepsy) disorders, we utilized primary enriched cultures of rat fetal (E 17) hippocampal neurons

to determine whether an analog of TRH, 3-Methyl-Histidine TRH (3Me-H TRH) or TRH-NPs given concurrently with Glu would protect such neurons against cell damage and cell death. 3Me-H TRH or TRH-NPs, when co-treated with 500 μ M Glu protected fetal neurons against cell death in a concentration-dependent manner.

In conclusion, we have developed a novel method to detect and characterize the time-course, distribution and concentration of fluorescent compounds released from NPs throughout the CNS over time in the brain following intranasal delivery. We have also shown that intranasal delivery of 3Me-H TRH can attenuate multiple seizure characteristics over short durations and that TRH-NPs may be a viable means to suppress the development of epileptogenesis/kindling acquisition over much longer periods of time. Finally, we have demonstrated that the mechanism of TRH's neuroprotective (anti-epileptic) effects, in part, involves modulation of glutamate toxicity.

Michael Kubek, Ph.D.
(Chairperson)

TABLE OF CONTENTS

1. Introduction	1
1.1. Epilepsy.....	1
1.1.1. Partial epilepsy.....	1
1.1.2. Generalized epilepsy.....	2
1.1.3. Intractable epilepsy syndromes of childhood.....	3
1.1.3.1 Current intractable seizure therapies.....	5
1.2. Animal seizure models.....	7
1.2.1. Acute seizure models.....	9
1.2.2. Chronic seizure models.....	10
1.2.2.1. Post-status epilepticus models.....	10
1.2.2.2. Electrical Kindling.....	11
1.3. Neuropeptides and epilepsy.....	14
1.3.1. Overview.....	14
1.3.2. Thyrotropin-releasing hormone (TRH) and Epilepsy.....	15
1.3.3. TRH and 3Me-H TRH.....	16
1.3.3.1. Neuroendocrine function of TRH.....	17
1.3.3.2. TRH distribution in the CNS.....	17
1.3.3.3. Metabolism of TRH.....	18
1.3.3.4. TRH Receptor.....	20
1.3.3.4.1. Regional distribution of the TRH receptor.....	22
1.3.3.4.2. TRH receptor signal transduction.....	23
1.3.3.4.3. TRH receptor desensitization/downregulation.....	25
1.3.3.5. Non endocrine roles of TRH.....	27
1.3.3.5.1. Neuroprotection.....	27
1.3.3.5.2. Depression.....	28
1.3.3.5.3. Analepsis.....	29
1.3.3.5.4. Memory.....	30
1.3.3.5.5. Antinocioception.....	31
1.3.3.5.6. Feeding.....	32
1.4. Problems in neuropeptide drug development.....	33
1.4.1. Routes of neuropeptide delivery.....	33
1.4.2. Intranasal drug delivery.....	36
1.4.2.1. Background.....	37
1.4.2.2. General overview of nasal anatomy and physiology.....	37
1.4.2.2.1. The vestibule.....	38
1.4.2.2.2. The respiratory epithelium.....	38
1.4.2.2.3. The glands of the nasal epithelium.....	39
1.4.2.2.4. The olfactory epithelium.....	39
1.4.2.2.4.1. Sustentacular supporting cells.....	41

1.4.2.2.4.2. Neurons and basal cells.....	41
1.4.2.2.4.3. Lamina propria.....	43
1.4.2.2.5. The cribiform plate.....	43
1.4.2.4. Neuroanatomy of the olfactory bulbs.....	43
1.4.2.5. Nose-brain barrier versus the BBB.....	44
1.4.2.6. Three routes of travel from nose to brain.....	45
1.4.5.2.6.1. Transport within the olfactory nerve pathway.....	45
1.4.5.2.6.2. Entry into the CSF via the non-neuronal olfactory epithelial pathway.....	46
1.4.5.2.6.3. Systemic entry via the non-neuronal olfactory epithelial pathway.....	47
1.4.2.7. Evidence for direct nose-to-brain transport.....	47
1.5. Sustained release preparations in delivery of neuropeptides.....	51
1.6. Methods of intranasal drug delivery in animals.....	54
2. Hypothesis.....	57
Given the evidence presented above, we propose the following two hypotheses:	
1) Intranasal administration of sustained-release biodegradable TRH nanoparticles during kindling development and/or to fully-kindled (epileptic) animals attenuates seizure duration and/or severity and 2) The neuroprotective (anti-epileptic) mechanism of action of TRH, in part, involves modulation of glutamate excitotoxicity.	
3. Materials and Methods.....	58
3.1. Nanoparticle preparation and characterization.....	58
3.1.1. D,L PLA materials.....	58
3.1.2. Preparation of 100 nm D,L PLA nanoparticles loaded with Nile red.....	58
3.1.3. Preparation of 560 nm D,L PLA nanoparticles loaded with Nile red.....	58
3.1.4. Preparation of 20 nm Fluospheres.....	59
3.1.5. Fluorescence Microscopy.....	59
3.1.6. Preparation of 100 nm D,L PLA nanoparticles loaded with TRH.....	60
3.1.7. Characterization of TRH nanoparticles using TEM.....	62
3.1.8. TRH nanoparticle characterization via immunocytochemistry.....	62
3.2. Neuronal cell culture.....	65
3.2.1. Dissection, processing, and plating.....	65
3.2.1. Culture media.....	66
3.2.3. Neuronal harvest following drug treatments.....	66
3.2.4. Cell viability assay.....	66
3.2.5. Lactate dehydrogenase assay.....	67
3.3. Kindling procedure.....	67
3.3.1. Animals.....	67
3.3.2. Electrode implantation procedure into the basolateral amygdalae.....	67

3.3.3. Electrode verification procedure.....	68
3.3.4. Nasal cannula implantation procedure.....	72
3.3.5. Kindling.....	72
3.4. Intranasal administration.....	73
4. Experimental Design.....	76
4.1. <i>In vitro</i> 3Me-H TRH protection studies	76
4.2. <i>In vitro</i> TRH nanoparticle protection study.....	77
4.3. Nanoparticle characterization.....	77
4.3.1. Uptake, subregional distribution and time-course of intranasally Delivered Nile-red sustained-release nanoparticles in the rat brain.....	77
4.3.2. <i>In vitro</i> neuronal PLA nanoparticle/fluosphere uptake.....	78
4.3.3. Size characterization of TRH nanoparticles using transmission electron microscopy.....	79
4.3.4. TRH nanoparticle Immunocytochemistry.....	79
4.4. Effects of soflurane and halothane studies on kindled seizures.....	80
4.5. Effects of intranasal 3Me-H TRH studies on kindled seizures.....	83
4.6. Effects of intranasal TRH nanoparticle on fully kindled Seizures.....	85
4.7. Effects of intranasal TRH nanoparticle studies on kindled epileptogenesis.....	87
5. Results.....	89
5.1. Effect of 3Me-H TRH on glutamate-induced toxicity <i>in vitro</i>	89
5.2. Effect of TRH nanoparticles on glutamate-induced toxicity <i>in vitro</i>	94
5.3. Nanoparticle Characterization.....	96
5.3.1. Uptake, subregional distribution and time-course of intranasally delivered Nile-red nanoparticles in the rat brain.....	96
5.3.2. Uptake of Nile red nanoparticles and polystyrene fluobeads into fetal hippocampal neurons <i>in vitro</i>	99
5.3.3. Size characterization of TRH nanoparticles using transmission electron microscopy.....	101
5.3.4. Immunostaining of TRH nanoparticles <i>in situ</i>	102
5.4. Effect of isoflurane and halothane on kindled seizures.....	104
5.5. Effect of intranasal 3Me-H TRH on fully kindled seizures.....	107
5.6. Effect of intranasal TRH nanoparticles on fully kindled Seizures.....	110
5.7. Effect of intranasal TRH nanoparticles on kindled epileptogenesis.....	115
6. Discussion.....	121
6.1. Effect of 3Me-H TRH on glutamate-induced toxicity <i>in vitro</i>	121
6.2. Effect of TRH-loaded nanoparticles on glutamate-induced toxicity <i>in vitro</i>	124
6.3. Nanoparticle Characterization.....	125
6.3.1. Characterization of Nile red nanoparticles in the brain following intranasal delivery as well as in neurons <i>in vitro</i>	125
6.3.3. Characterization of TRH nanoparticles <i>in vitro</i> using transmission electron microscopy and <i>in situ</i> using imunohistochemistry.....	129
6.4. Effect of isoflurane and halothane on kindled seizures.....	130

6.5. Effect of intranasal 3Me-H TRH on fully kindled seizures..... 133
6.6. Effect of intranasal TRH nanoparticles on fully kindled Seizures.....136
6.7. Effect of intranasal TRH nanoparticles on kindled epileptogenesis.....137

7. Summary.....140

8. Conclusions.....140

9. Bibliography..... 143

Curriculum Vitae